Article Information
- Received March 18, 2024
- Revision received May 28, 2024
- Accepted May 30, 2024
- Published online June 6, 2024.
Author Information
- 1Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5B7, Canada
- 2Department of Experimental Psychology, University of Cambridge, Cambridge CB2 1TN, United Kingdom
- 3MRC and Wellcome Trust Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge CB2 1TN, United Kingdom
- Correspondence should be addressed to Paul A. S. Sheppard at psheppa5{at}uwo.ca.
Author contributions
Author contributions: C.A.O., T.J.B., and L.M.S. designed research; C.A.O. performed research; P.A.S.S. analyzed data; P.A.S.S. and T.J.B. wrote the paper.
Disclosures
T.J.B. and L.M.S. have established a series of targeted cognitive tests for animals, administered via touchscreen within a custom environment known as the “Bussey–Saksida touchscreen chamber.” Cambridge Enterprise, the technology transfer office of the University of Cambridge, supported the commercialization of the Bussey–Saksida chamber, culminating in a license to Campden Instruments. Any financial compensation received from the commercialization of the technology is fully invested in further touchscreen development and/or maintenance. The authors declare no competing financial interests.
This work was funded by the EU Innovative Medicines Initiative (Ref. Number: 115008), Janssen Pharmaceuticals, and Natural Sciences and Engineering Research Council of Canada (RGPIN-2019-06087). The authors thank the members of the Translational Cognitive Neuroscience Lab for their help with behavioral testing and David Theobald for the assistance with surgeries and perfusions. Figure 1 was made using BioRender.com.
T.J.B.’s and L.M.S.’s present address: Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry and Robarts Research Institute, Western University, London, ON, Canada
Funding
Canadian Government | Natural Sciences and Engineering Research Council of Canada (NSERC)
RGPIN-2019-06087EU Innovative Medicines Initiative
115008Auris | J&J | Janssen UK (Janssen-Cilag Limited)
Other Version
- You are viewing the most recent version of this article.
- previous version (June 06, 2024).
Article usage
In this issue
